Literature DB >> 6830395

Successful therapy for rhinocerebral mucormycosis with associated bilateral brain abscesses.

R Hamill, L A Oney, L R Crane.   

Abstract

A case of extensive rhinocerebral mucormycosis, with associated bilateral brain abscesses, occurred in a man with diabetes. A Rhizopus sp grew from the initial nasal biopsy specimens. Successful therapy consisted of correcting metabolic acidosis, using serial computed tomographic (CT) scans to follow the progressive course of brain involvement from cerebritis to encapsulated abscesses, and performing successive biopsies to determine the adequacy of treatment. On 18-month follow-up, the patient had returned to full-time employment with minimal neurologic impairment. With CT scanning and aggressive therapy, rhinocerebral mucormycosis with bilateral brain involvement can be cured.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6830395

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  5 in total

Review 1.  Intracerebral Aspergillus abscess: case report and review of the literature.

Authors:  M Artico; F S Pastore; M Polosa; S Sherkat; M Neroni
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

Review 2.  Systemic zygomycosis.

Authors:  E W Benbow; R W Stoddart
Journal:  Postgrad Med J       Date:  1986-11       Impact factor: 2.401

3.  Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression.

Authors:  R Selby; C B Ramirez; R Singh; I Kleopoulos; S Kusne; T E Starzl; J Fung
Journal:  Arch Surg       Date:  1997-03

Review 4.  Opportunistic zygomycotic infections. A literature review.

Authors:  A Espinel-Ingroff; L A Oakley; T M Kerkering
Journal:  Mycopathologia       Date:  1987-01       Impact factor: 2.574

5.  Rhizopus arrhizus in Italy as the causative agent of primary cerebral zygomycosis in a drug addict.

Authors:  S Oliveri; E Cammarata; G Augello; P Mancuso; R Tropea; L Ajello; A A Padhye
Journal:  Eur J Epidemiol       Date:  1988-09       Impact factor: 8.082

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.